THE US Food and Drug
Administration has approved
Xeljanz (tofacitinib) to treat adults
with moderately to severely active
rheumatoid arthritis who have had
an inadequate response to, or who
are intolerant of, methotrexate.
The safety and effectiveness of
Xeljanz was evaluated in seven
clinical trials in adult patients with
moderately to severely active
rheumatoid arthritis.
In all of the trials, patients treated
with Xeljanz experienced
improvement in clinical response
and physical functioning compared
to patients treated with placebo.
The drug will however carry a
warning on its box about its
association with an increased risk
of serious infections, including
opportunistic infections.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Nov 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Nov 12
THE Australian Government has lowered the age of eligibility for its free National Bowel Cancer Screening Program (NBCSP) to 45, unlocking access to the test kits to more than 1.6 million Australians.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.